Overview

A Phase II Study of Safety and Efficacy of AMX0035 in Adult Patients With Wolfram Syndrome

Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This study is an open label Phase II study to evaluate the safety and efficacy of AMX0035 in adults with Wolfram syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Amylyx Pharmaceuticals Inc.
Treatments:
4-phenylbutyric acid